XTX Topco Ltd Makes New $1.10 Million Investment in GSK plc (NYSE:GSK)

XTX Topco Ltd bought a new position in GSK plc (NYSE:GSK - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 28,604 shares of the pharmaceutical company's stock, valued at approximately $1,101,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Register Financial Advisors LLC bought a new position in shares of GSK in the first quarter worth about $31,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the second quarter worth approximately $37,000. Richardson Financial Services Inc. bought a new stake in shares of GSK in the fourth quarter valued at approximately $40,000. PrairieView Partners LLC bought a new stake in shares of GSK in the second quarter valued at approximately $47,000. Finally, Triad Wealth Partners LLC acquired a new stake in shares of GSK in the second quarter worth $49,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

Shares of GSK traded down $0.82 during mid-day trading on Friday, reaching $40.80. The company had a trading volume of 5,028,061 shares, compared to its average volume of 3,582,050. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The company has a market capitalization of $84.56 billion, a P/E ratio of 14.78, a P/E/G ratio of 1.41 and a beta of 0.66. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The company's 50-day moving average is $41.39 and its 200-day moving average is $41.68.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. On average, equities analysts anticipate that GSK plc will post 4.15 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be given a $0.3843 dividend. The ex-dividend date is Friday, August 16th. This is a positive change from GSK's previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a yield of 3.77%. GSK's payout ratio is 54.71%.

Analyst Upgrades and Downgrades

GSK has been the topic of several research analyst reports. Jefferies Financial Group raised their price target on shares of GSK from $52.50 to $53.00 and gave the stock a "buy" rating in a research report on Tuesday, July 2nd. The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They set a "neutral" rating and a $47.00 price target on the stock. Citigroup upgraded GSK to a "strong-buy" rating in a research report on Monday, June 24th. UBS Group lowered GSK from a "buy" rating to a "neutral" rating in a report on Monday, July 8th. Finally, Argus upgraded GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Four analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, GSK has an average rating of "Buy" and a consensus target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.